Korean Drug Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	62,509	73,001	81,375	79,984	74,466
Other Revenue	-0	-	-0	-0	-0
Revenue	62,509	73,001	81,375	79,984	74,466
Revenue Growth (YoY)	-14.37%	-10.29%	1.74%	7.41%	11.49%
Cost of Revenue	35,908	38,600	44,025	45,467	43,400
Gross Profit	26,601	34,401	37,350	34,517	31,065
Selling, General & Admin	18,874	24,137	18,136	19,111	18,529
Amortization of Goodwill & Intangibles	18.41	169.6	197.35	156.68	248.27
Other Operating Expenses	494.93	677.64	724.2	662	745.93
Operating Expenses	19,687	30,296	30,630	20,188	19,799
Operating Income	6,913	4,105	6,720	14,329	11,266
Interest Expense	-3.88	-4.24	-3.02	-2.1	-1.53
Interest & Investment Income	657.64	594.69	1,213	621.01	133.66
Currency Exchange Gain (Loss)	-4.08	3.48	1.55	84.73	98.22
Other Non Operating Income (Expenses)	414.91	218.47	205.88	32.88	182.37
EBT Excluding Unusual Items	7,978	4,917	8,137	15,066	11,679
Gain (Loss) on Sale of Investments	-180.6	72.9	132.87	-383.6	-359.46
Gain (Loss) on Sale of Assets	0.31	3.56	-4.78	2.81	1.13
Pretax Income	7,797	4,994	8,265	14,685	11,321
Income Tax Expense	1,285	1,998	13,182	2,876	2,278
Net Income	6,512	2,995	-4,917	11,809	9,042
Net Income to Common	6,512	2,995	-4,917	11,809	9,042
Net Income Growth	117.42%	-	-	30.59%	22.86%
Shares Outstanding (Basic)	-	11	11	11	11
Shares Outstanding (Diluted)	-	11	11	11	11
Shares Change (YoY)	-	0.08%	-0.01%	-1.30%	0.56%
EPS (Basic)	-	277.55	-455.98	1095.09	827.64
EPS (Diluted)	-	277.55	-455.98	1095.09	827.64
EPS Growth	-	-	-	32.31%	22.18%
Free Cash Flow	12,653	3,842	-7,812	-180.15	7,660
Free Cash Flow Per Share	-	356.01	-724.50	-16.71	701.12
Gross Margin	42.55%	47.12%	45.90%	43.16%	41.72%
Operating Margin	11.06%	5.62%	8.26%	17.91%	15.13%
Profit Margin	10.42%	4.10%	-6.04%	14.76%	12.14%
Free Cash Flow Margin	20.24%	5.26%	-9.60%	-0.22%	10.29%
EBITDA	8,882	6,174	8,469	15,712	12,736
EBITDA Margin	14.21%	8.46%	10.41%	19.64%	17.10%
D&A For EBITDA	1,969	2,069	1,749	1,383	1,470
EBIT	6,913	4,105	6,720	14,329	11,266
EBIT Margin	11.06%	5.62%	8.26%	17.91%	15.13%
Effective Tax Rate	16.48%	40.02%	159.49%	19.58%	20.13%
Advertising Expenses	105.78	900.89	920.23	1,014	1,082

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.